Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium-Reference-Cited by-同舟云学术

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

Published:2023-08-01 Issue:1 Volume:12 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Jiang Yuanhong,Wu Siyu,Li Rong,Yu Jiazheng,Zheng Jianyi,Li Zeyu,Li Mingyang,Xin Kerong,Xu Zhenqun,Li Shijie,Chen Xiaonan

Abstract

AbstractNumerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/s40164-023-00430-1.pdf

Reference9 articles.

1. Juzeniene A, Stenberg VY, Bruland ØS et al. Preclinical and clinical status of PSMA-Targeted alpha therapy for metastatic castration-resistant prostate Cancer. Cancers (Basel). 2021;13(4).

2. Tagawa ST, Thomas C, Adra N, et al. Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2023;41(6suppl):LBA21–LBA.

3. Sun MP, Nauseef JT, Palmer J, et al. Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. J Clin Oncol. 2023;41(6suppl):181.

4. Yilmaz M, Ravandi F. The potential role of bi-specific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol. 2020;33(4):101218.

5. Luke JJ, Sharma M, Chandana SR, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a phase 1 expansion (exp) cohort. J Clin Oncol. 2023;41(6suppl):155.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision targeting in oncology: The future of conjugated drugs;Biomedicine & Pharmacotherapy;2024-08

2. Double hit — bispecific antibodies in cancer therapy;Oncology in Clinical Practice;2024-05-31